Literature DB >> 21227391

Optimized allele-specific real-time PCR assays for the detection of common mutations in KRAS and BRAF.

Alois H Lang1, Heinz Drexel, Simone Geller-Rhomberg, Nicole Stark, Thomas Winder, Kathrin Geiger, Axel Muendlein.   

Abstract

Mutations in the oncogenes KRAS and BRAF have been identified as prognostic factors in patients with colorectal diseases and as predictors of negative outcome in epidermal growth factor receptor-targeted therapies. Therefore, accurate mutation detection in both genes, KRAS and BRAF, is of increasing clinical relevance. We aimed at optimizing allele-specific real-time PCR assays for the detection of common mutations in KRAS and the BRAF Val600Glu mutation using allele-specific PCR primers for allelic discrimination and probes (TaqMan) for quantification. Each reaction mix contains a co-amplified internal control to exclude false-negative results. Allele-specific real-time PCR assays were evaluated on plasmid model systems providing a mutation detection limit of 10 copies of mutant DNA in proportions as low as 1% of the total DNA. Furthermore, we analyzed 125 DNA samples prepared from archived, formalin-fixed, paraffin-embedded colorectal carcinomas and compared results with those obtained from direct-sequence analysis. All mutations determined by sequence analysis could be recovered by allele-specific PCR assays. In addition, allele-specific PCR assays clearly identified three additional samples affected by a mutation. We propose these allele-specific real-time PCR assays as a low-cost and fast diagnostic tool for accurate detection of KRAS and BRAF mutations that can be applied to clinical samples. Copyright Â
© 2011 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21227391      PMCID: PMC3070579          DOI: 10.1016/j.jmoldx.2010.11.007

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  21 in total

1.  Mode of action and application of Scorpion primers to mutation detection.

Authors:  N Thelwell; S Millington; A Solinas; J Booth; T Brown
Journal:  Nucleic Acids Res       Date:  2000-10-01       Impact factor: 16.971

2.  BRAF mutation in metastatic colorectal cancer.

Authors:  Jolien Tol; Iris D Nagtegaal; Cornelis J A Punt
Journal:  N Engl J Med       Date:  2009-07-02       Impact factor: 91.245

3.  Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

Authors:  Pierre Laurent-Puig; Anne Cayre; Gilles Manceau; Emmanuel Buc; Jean-Baptiste Bachet; Thierry Lecomte; Philippe Rougier; Astrid Lievre; Bruno Landi; Valérie Boige; Michel Ducreux; Marc Ychou; Fréderic Bibeau; Olivier Bouché; Julia Reid; Steven Stone; Frédérique Penault-Llorca
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

4.  K-ras point mutation detection in lung cancer: comparison of two approaches to somatic mutation detection using ARMS allele-specific amplification.

Authors:  S J Clayton; F M Scott; J Walker; K Callaghan; K Haque; T Liloglou; G Xinarianos; S Shawcross; P Ceuppens; J K Field; J C Fox
Journal:  Clin Chem       Date:  2000-12       Impact factor: 8.327

5.  Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors.

Authors:  Martin Pichler; Marija Balic; Elke Stadelmeyer; Christoph Ausch; Martina Wild; Christian Guelly; Thomas Bauernhofer; Hellmut Samonigg; Gerald Hoefler; Nadia Dandachi
Journal:  J Mol Diagn       Date:  2009-02-12       Impact factor: 5.568

6.  Different types of K-Ras mutations are conversely associated with overall survival in patients with colorectal cancer.

Authors:  Thomas Winder; Axel Mündlein; Simone Rhomberg; Klaus Dirschmid; Bernd L Hartmann; Michael Knauer; Heinz Drexel; Etienne Wenzl; Alexander De Vries; Alois Lang
Journal:  Oncol Rep       Date:  2009-05       Impact factor: 3.906

7.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

8.  Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study.

Authors:  H J Andreyev; A R Norman; D Cunningham; J Oates; B R Dix; B J Iacopetta; J Young; T Walsh; R Ward; N Hawkins; M Beranek; P Jandik; R Benamouzig; E Jullian; P Laurent-Puig; S Olschwang; O Muller; I Hoffmann; H M Rabes; C Zietz; C Troungos; C Valavanis; S T Yuen; J W Ho; C T Croke; D P O'Donoghue; W Giaretti; A Rapallo; A Russo; V Bazan; M Tanaka; K Omura; T Azuma; T Ohkusa; T Fujimori; Y Ono; M Pauly; C Faber; R Glaesener; A F de Goeij; J W Arends; S N Andersen; T Lövig; J Breivik; G Gaudernack; O P Clausen; P D De Angelis; G I Meling; T O Rognum; R Smith; H S Goh; A Font; R Rosell; X F Sun; H Zhang; J Benhattar; L Losi; J Q Lee; S T Wang; P A Clarke; S Bell; P Quirke; V J Bubb; J Piris; N R Cruickshank; D Morton; J C Fox; F Al-Mulla; N Lees; C N Hall; D Snary; K Wilkinson; D Dillon; J Costa; V E Pricolo; S D Finkelstein; J S Thebo; A J Senagore; S A Halter; S Wadler; S Malik; K Krtolica; N Urosevic
Journal:  Br J Cancer       Date:  2001-09-01       Impact factor: 7.640

9.  KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

Authors:  F Loupakis; A Ruzzo; C Cremolini; B Vincenzi; L Salvatore; D Santini; G Masi; I Stasi; E Canestrari; E Rulli; I Floriani; K Bencardino; N Galluccio; V Catalano; G Tonini; M Magnani; G Fontanini; F Basolo; A Falcone; F Graziano
Journal:  Br J Cancer       Date:  2009-07-14       Impact factor: 7.640

10.  High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue.

Authors:  Jolien Tol; Jeroen R Dijkstra; Marianne E Vink-Börger; Iris D Nagtegaal; Cornelis J A Punt; Johan H J M Van Krieken; Marjolijn J L Ligtenberg
Journal:  J Cell Mol Med       Date:  2010-05-13       Impact factor: 5.310

View more
  32 in total

1.  Absence of BRAF mutation in pheochromocytoma and paraganglioma.

Authors:  T Vosecka; A Vicha; T Zelinka; P Jencova; K Pacak; J Duskova; J Benes; A Guha; L Stanek; M Kohoutova; Z Musil
Journal:  Neoplasma       Date:  2017       Impact factor: 2.575

Review 2.  Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie.

Authors:  Jonathan M Loree; Scott Kopetz; Kanwal P S Raghav
Journal:  J Gastrointest Oncol       Date:  2017-02

3.  Molecular analysis of BRAF V600E mutation in multiple nodules of pulmonary Langerhans cell histiocytosis.

Authors:  Arno Dimmler; Helene Geddert; Martin Werner; Gerhard Faller
Journal:  Virchows Arch       Date:  2017-02-20       Impact factor: 4.064

4.  Validation Strategy for Ultrasensitive Mutation Detection.

Authors:  Marija Debeljak; Michael Noë; Stacy L Riel; Lisa M Haley; Alexis L Norris; Derek A Anderson; Emily M Adams; Masaya Suenaga; Katie F Beierl; Ming-Tseh Lin; Michael G Goggins; Christopher D Gocke; James R Eshleman
Journal:  Mol Diagn Ther       Date:  2018-10       Impact factor: 4.074

Review 5.  Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology.

Authors:  Antonia R Sepulveda; Stanley R Hamilton; Carmen J Allegra; Wayne Grody; Allison M Cushman-Vokoun; William K Funkhouser; Scott E Kopetz; Christopher Lieu; Noralane M Lindor; Bruce D Minsky; Federico A Monzon; Daniel J Sargent; Veena M Singh; Joseph Willis; Jennifer Clark; Carol Colasacco; R Bryan Rumble; Robyn Temple-Smolkin; Christina B Ventura; Jan A Nowak
Journal:  J Mol Diagn       Date:  2017-02-06       Impact factor: 5.568

6.  Evaluation of INK4A promoter methylation using pyrosequencing and circulating cell-free DNA from patients with hepatocellular carcinoma.

Authors:  Gengming Huang; Joseph D Krocker; Jason L Kirk; Shehzad N Merwat; Hyunsu Ju; Roger D Soloway; Lucas R Wieck; Albert Li; Anthony O Okorodudu; John R Petersen; Nihal E Abdulla; Andrea Duchini; Luca Cicalese; Cristiana Rastellini; Peter C Hu; Jianli Dong
Journal:  Clin Chem Lab Med       Date:  2014-06       Impact factor: 3.694

7.  BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome.

Authors:  Christopher W Toon; Michael D Walsh; Angela Chou; David Capper; Adele Clarkson; Loretta Sioson; Stephen Clarke; Scott Mead; Rhiannon J Walters; Mark Clendenning; Christophe Rosty; Joanne P Young; Aung Ko Win; John L Hopper; Ashley Crook; Andreas von Deimling; Mark A Jenkins; Daniel D Buchanan; Anthony J Gill
Journal:  Am J Surg Pathol       Date:  2013-10       Impact factor: 6.394

8.  A more sensitive platform for the detection of low-abundance BRAF(V⁶⁰⁰E) mutations.

Authors:  Weiqin Jiang; Weibin Wang; Fangfang Fu; Xiaodong Teng; Haohao Wang; Haiyong Wang; Lisong Teng
Journal:  Mol Cell Biochem       Date:  2012-03-15       Impact factor: 3.396

9.  Molecular Biomarkers for the Evaluation of Colorectal Cancer.

Authors:  Antonia R Sepulveda; Stanley R Hamilton; Carmen J Allegra; Wayne Grody; Allison M Cushman-Vokoun; William K Funkhouser; Scott E Kopetz; Christopher Lieu; Noralane M Lindor; Bruce D Minsky; Federico A Monzon; Daniel J Sargent; Veena M Singh; Joseph Willis; Jennifer Clark; Carol Colasacco; R Bryan Rumble; Robyn Temple-Smolkin; Christina B Ventura; Jan A Nowak
Journal:  Am J Clin Pathol       Date:  2017-02-03       Impact factor: 2.493

10.  Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing.

Authors:  Allison M Cushman-Vokoun; Daniel G Stover; Zhiguo Zhao; Elizabeth A Koehler; Jordan D Berlin; Cindy L Vnencak-Jones
Journal:  Clin Colorectal Cancer       Date:  2013-06-14       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.